7-days of FREE Audio papers, translation & more with Prime
7-days of FREE Prime access
7-days of FREE Audio papers, translation & more with Prime
7-days of FREE Prime access
https://doi.org/10.4103/0028-3886.181567
Copy DOIJournal: Neurology India | Publication Date: Jan 1, 2016 |
Citations: 4 |
Recanalization therapies have been increasingly applied in clinical practice, which might change the outcomes of patients with large middle cerebral artery (MCA) infarction. The purpose of this study was to study the clinical course, prognostic factors, and long-term outcomes of patients with an acute large MCA infarction. Patients with an acute large MCA infarction who were treated between January, 2011 - March, 2014 were studied. The demographics and vascular risk factors were compared between patients with and without clinical outcomes of interest, favorable outcome and death. From a total of 1538 patients, 200 patients with large MCA infarction were included. The mean age was 67 years. The mean National Institute of Health Stroke Scale score was 20. The mean time from onset to the hospital was 289 min. Intravenous recombinant-tissue-plasminogen activator (rtPA) was given in 50 patients (25%). The mean follow-up time was 13 months. 51 patients (51/191, 27%) had a favorable outcome (modified Rankin Scale 0-2) at the final follow-up. 81 patients (81/191, 42%) died. A younger age, less severe stroke, rtPA treatment, and large-artery atherosclerosis stroke subtype were related to a favorable outcome. Older age and presence of coronary artery disease were associated with death and rtPA treatment was inversely related to death. Prognosis of patients with a large MCA infarction is still poor. Favorable outcomes were found in only a fourth of the total patients, and a high mortality rate was still present. Intravenous rtPA treatment seemed to be related to a favorable outcome.
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.